Real-world outcomes in historically underserved patients with chronic hepatitis&nbsp;C infection treated with Glecaprevir/Pibrentasvir

Aghemo, Alessio; Horsmans, Yves; Bourgeois, Stefan; Bondin, Mark; Gschwantler, Michael; Hofer, Harald; Semmo, Nasser; Negro, Francesco; Zhang, Zhenzhen; Marcinak, John; Veitsman, Ella; Hazzan, Rawi; Mimidis, Konstantinos; Goulis, Ioannis; Marques, Nuno; Flisiak, Robert; Mazur, Wlodzimierz; Roncero, Carlos; Marra, Fiona; Pageaux, Georges Philippe; Asselah, Tarik; Lampertico, Pietro

doi:10.1007/s40121-021-00455-1

Scientific article

English

Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir

Published inInfectious Diseases and Therapy

Publication date2021

Abstract

Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1-6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient populations, focusing on persons who use drugs infected with HCV.

Affiliation entities

Research groups

Etudes et traitement de l'hépatite C et B (554)

Citation (ISO format)

AGHEMO, Alessio et al. Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir. In: Infectious Diseases and Therapy, 2021. doi: 10.1007/s40121-021-00455-1

Article (Published version)

CC BY

Identifiers

PID : unige:152660
DOI : 10.1007/s40121-021-00455-1
PMID : 34125405

Journal ISSN2193-6382

247views

113downloads

Creation17/06/2021 15:04:00

First validation17/06/2021 15:04:00

Update16/03/2023 00:48:49

Status update16/03/2023 00:48:47

Last indexation31/10/2024 22:26:02

Archive ouverte UNIGE

Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir

Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1-6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient populations, focusing on persons who use drugs infected with HCV.

Technical informations